Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

IMProving User experience, Long-term sustainability and Services of EU-OPENSCREEN

Project description

Driving the next generation of drug discovery

Developing new medicines requires faster and more reliable ways to test compounds and study disease biology. While inconsistent results and limited access to the latest technologies challenge early-stage drug discovery, advances in high-throughput screening, computational analysis, and genetic tools offer new opportunities to speed up research and improve outcomes. The EU-funded IMPULSE project aims to make tools widely available. Specifically, it will combine new chemical approaches with advanced cell models and screening methods. The project’s overall goal is to secure more reliable data, better training, and a more efficient way for researchers across Europe to work together and create new medicines.

Objective

EU-OPENSCREEN (EU-OS), the distributed European Research Infrastructure for Chemical Biology and early drug discovery, provides world-class services in high-throughput compound screening and medicinal chemistry to users from academia and industry. As one of the largest open-access initiative globally, EU-OPENSCREEN plays an increasingly important role in facilitating early stage drug discovery in Europe. It recently integrated fragment-based drug discovery and chemoproteomics as two new services, but the increasing complexity of modern drug discovery projects requires an even more comprehensive portfolio and integration of emerging technologies. To ensure that EU-OS continues to offer a comprehensive suite of relevant services and support a growing user community to conduct forefront research, IMPULSE will develop, validate and integrate new services in AI/ML, new chemical modalities, and innovative disease-relevant cell models combined with CRISPR-Cas9/RNAi-based genetic screening. IMPULSE will work towards the implementation of common operational and data standards to increase data reproducibility and FAIRness. Bespoke outreach and training activities will raise awareness among key user groups of its new services and advance operational excellence and reproducibility in pre-clinical drug discovery. New models for pre-competitive drug discovery with industry or charities, and growing ERIC member community will reinforce the sustainability and accessibility of EU-OPENSCREEN.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-INFRA-2023-DEV-01

See all projects funded under this call

Coordinator

EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC)
Net EU contribution
€ 1 035 215,81
Address
ROBERT-ROSSLE-STR. 10
13125 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
€ 1 294 019,76

Participants (24)